Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for CNS disorders, has announced its participation in two major investor conferences in March 2025.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference in Boston, featuring a fireside chat on March 4, 2025, from 3:10-3:40pm EST
- The Stifel 2025 Virtual CNS Forum, with a fireside chat scheduled for March 19, 2025, from 10:30-10:55am EST
Investors and interested parties can access live and archived webcasts of both presentations through the Investors section of Rapport's website at investors.rapportrx.com.
Rapport Therapeutics (Nasdaq: RAPP), una compagnia biotech in fase clinica focalizzata nello sviluppo di medicinali di precisione a piccole molecole per disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025.
La compagnia parteciperà a:
- La 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston, con un incontro informale previsto per il 4 marzo 2025, dalle 15:10 alle 15:40 EST
- Il Forum Virtuale CNS 2025 di Stifel, con un incontro informale programmato per il 19 marzo 2025, dalle 10:30 alle 10:55 EST
Investitori e parti interessate possono accedere alle trasmissioni in diretta e registrate di entrambe le presentazioni attraverso la sezione Investitori del sito web di Rapport all'indirizzo investors.rapportrx.com.
Rapport Therapeutics (Nasdaq: RAPP), una empresa biotecnológica en etapa clínica centrada en el desarrollo de medicamentos de precisión de pequeñas moléculas para trastornos del sistema nervioso central, ha anunciado su participación en dos importantes conferencias de inversores en marzo de 2025.
La empresa participará en:
- La 45ª Conferencia Anual de Salud de TD Cowen en Boston, con una charla informal programada para el 4 de marzo de 2025, de 3:10 a 3:40 p.m. EST
- El Foro Virtual CNS 2025 de Stifel, con una charla informal programada para el 19 de marzo de 2025, de 10:30 a 10:55 a.m. EST
Los inversores y partes interesadas pueden acceder a las transmisiones en vivo y grabadas de ambas presentaciones a través de la sección de Inversores del sitio web de Rapport en investors.rapportrx.com.
Rapport Therapeutics (Nasdaq: RAPP)는 중추신경계 장애를 위한 소분자 정밀 약물 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2025년 3월 두 개의 주요 투자자 회의에 참석할 예정이라고 발표했습니다.
회사는 다음 회의에 참석합니다:
- TD Cowen 제45회 연례 건강 관리 회의는 보스턴에서 2025년 3월 4일 오후 3시 10분부터 3시 40분까지 EST에 진행됩니다.
- Stifel 2025 가상 CNS 포럼은 2025년 3월 19일 오전 10시 30분부터 10시 55분까지 EST에 진행될 예정입니다.
투자자 및 관심 있는 당사자는 Rapport 웹사이트의 투자자 섹션을 통해 두 프레젠테이션의 실시간 및 기록된 웹캐스트에 접근할 수 있습니다: investors.rapportrx.com.
Rapport Therapeutics (Nasdaq: RAPP), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments de précision à petites molécules pour les troubles du système nerveux central, a annoncé sa participation à deux importantes conférences pour investisseurs en mars 2025.
L'entreprise participera à :
- La 45e Conférence Annuelle sur la Santé de TD Cowen à Boston, avec une discussion informelle prévue le 4 mars 2025, de 15h10 à 15h40 EST
- Le Forum Virtuel CNS 2025 de Stifel, avec une discussion informelle programmée pour le 19 mars 2025, de 10h30 à 10h55 EST
Les investisseurs et les parties intéressées peuvent accéder aux webcasts en direct et enregistrés des deux présentations via la section Investisseurs du site web de Rapport à l'adresse investors.rapportrx.com.
Rapport Therapeutics (Nasdaq: RAPP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Präzisionsmedikamenten in Form von kleinen Molekülen für Störungen des zentralen Nervensystems konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben.
Das Unternehmen wird an folgenden Veranstaltungen teilnehmen:
- Der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston, die am 4. März 2025 von 15:10 bis 15:40 Uhr EST stattfinden wird.
- Das Stifel 2025 virtuelle CNS-Forum, mit einer informellen Gesprächsrunde, die für den 19. März 2025 von 10:30 bis 10:55 Uhr EST geplant ist.
Investoren und Interessierte können die Live- und aufgezeichneten Webcasts beider Präsentationen über den Investorenbereich der Webseite von Rapport unter investors.rapportrx.com abrufen.
- None.
- None.
BOSTON and SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences in March 2025.
TD Cowen 45th Annual Health Care Conference (Boston) – fireside chat on Tuesday, March 4, 2025, at 3:10-3:40pm EST.
Stifel 2025 Virtual CNS Forum – fireside chat on Wednesday, March 19, 2025, at 10:30-10:55am EST.
Interested parties may access the live and archived webcasts under the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
FAQ
When is Rapport Therapeutics (RAPP) presenting at the TD Cowen Healthcare Conference in March 2025?
What time is Rapport Therapeutics (RAPP) presenting at the Stifel Virtual CNS Forum in March 2025?
How can investors access Rapport Therapeutics (RAPP) conference presentations in March 2025?
Which investor conferences is Rapport Therapeutics (RAPP) attending in March 2025?
What type of medicines does Rapport Therapeutics (RAPP) develop?
